Johnson & Johnson (NYSE:JNJ) on Wednesday announced that the U.S. Food and Drug Administration (FDA) approved Imaavy (nipocalimab-aahu) as a treatment for generalized myasthenia gravis (gMG), an autoimmune disease.
Accordingly, J&J (NYSE:JNJ) will introduce a new treatment option for
